Arcturus Therapeutics Logo
US03969T1097
A2PMAS
ARCT

Arcturus Therapeutics

Previsión

El precio objetivo medio de los analistas es de 27,80 € (+309,43 %). La mediana es de 27,80 € (+309,43 %).

Comprar
  12
Mantener
  5
Vender
  4

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Arcturus Therapeutics presents pipeline at Cantor conference; pivotal data expected soon

    Arcturus Therapeutics presented three core programs at the Cantor Global Healthcare Conference: ARCT-810 for OTC deficiency, an inhaled mRNA program for cystic fibrosis (CF), and a self-amplifying mRNA platform with commercial vaccine success. Near-term catalysts include the Phase II readout for ARCT-810 expected later this month, FDA feedback, and a fourth-quarter decision on whether to continue the CF program — a move that could trigger funding from Thermo Fisher. Management highlights technological advantages (biodegradable LNPs, improved mRNA purification, a tailored nebulizer) but still sees risks around efficacy, safety and competition. » Más en de.investing.com


  • Arcturus Therapeutics sees 2026 as a turning point with two near-term catalysts

    At the Citigroup conference, Arcturus Therapeutics announced two near-term catalysts: Phase II data on OTC deficiency in September and a go/no-go decision on initiating Phase III for cystic fibrosis in the fourth quarter. The inhaled mRNA platform was presented as differentiated after safety and tolerability issues were addressed. Thermo Fisher has committed up to $40 million to non-dilutively support the Phase III cystic fibrosis development in exchange for exclusive manufacturing rights. The vaccine business provides non-dilutive revenue to fund the therapeutic pipeline; substantial CF data are expected in early 2025. » Más en de.investing.com


  • Arcturus Therapeutics jumps after management signal and conference announcements

    Arcturus Therapeutics’ stock rose intraday by about 10–13% after management announced participation in five major investor conferences in September, viewed as a vote of confidence in the pipeline. Key clinical milestones for ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency) are approaching. Analyst support, better-than-expected quarterly results, more than $191 million in cash and a strategic manufacturing agreement with Thermo Fisher bolster the funding outlook through 2028 and the credibility for a potential phase 3 study. The rally occurred despite a weaker broader market and appears to be company-specific. » Más en de.investing.com


  • Arcturus highlights strong liquidity and upcoming clinical catalysts

    Arcturus has more than $200 million in liquidity, giving it a funding runway into 2028 to support development of its programs. The company expects a Q4 2024 decision on advancing ARCT-032 (inhaled mRNA for cystic fibrosis) into phase III and anticipates data and regulatory guidance for ARCT-810 (OTC deficiency) before Sept. 30, 2024. The vaccine business, including KOSTAIVE (approved in 32 countries), has been returned to 100% strategic control and is intended to help fund the therapeutics pipeline. Arcturus is evaluating partnerships and has outlined a possible $40 million support from Thermo Fisher tied to a phase III decision. » Más en de.investing.com


  • Arcturus Therapeutics reduces quarterly loss more than expected despite 89% revenue drop

    Arcturus reported an adjusted loss of $0.84 per share in Q2 versus a consensus expectation of $1.05, beating estimates by 20%. Revenue fell to $2.96 million, a decline of 89.4% year‑on‑year after the end of the collaboration with CSL Seqirus. Cash and equivalents amounted to $191.5 million, securing a liquidity runway of more than 2.5 years. The company cut R&D spending, is advancing cystic fibrosis (ARCT‑032) and OTCD (ARCT‑810) programs, and expects Phase II/III decisions and data in the second half of 2026. » Más en de.investing.com

En 2012, Arcturus Therapeutics ya ha pagado 2,66 € en dividendos. El último pago fue en diciembre de 2012.

Datos financieros

En el último trimestre, Arcturus Therapeutics tuvo unos ingresos de 16,15 M € y un beneficio neto de -6,55 M €

(EUR) septiembre de 2026
YoY
Ingresos 16,15 M 10,53 %
Beneficio bruto 16,15 M 37,28 %
Beneficio neto -6,55 M 42,88 %
EBITDA -6,55 M 39,45 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
211,19 M €
Número de acciones
28,82 M
Máximo/mínimo de 52 semanas
16,37 € - 5,01 €
Dividendos No
Beta
2,61
Ratio P/E
-2,59
Ratio PEG
0,10
Ratio P/B
1,36
Ratio P/S
9,29

Perfil de la empresa

Arcturus Therapeutics Holdings Inc., una empresa de medicamentos de ARN, se centra en el desarrollo de vacunas para enfermedades infecciosas, y de medicamentos para enfermedades hepáticas y respiratorias raras en Estados Unidos. Los programas de desarrollo de la compañía comprenden el programa de desarrollo LUNAR-OTC para el déficit de ornitina transcarbamilasa (OTC); y el programa LUNAR-CF para la enfermedad pulmonar de fibrosis quística causada por mutaciones en el gen del regulador de la conductancia transmembrana de la fibrosis quística (CFTR), además de programas de vacunas que incluyen LUNAR-COV19 y LUNAR-FLU. Tiene alianzas de colaboración con Vinbiocare Biotechnology Joint Stock Company para la fabricación de vacunas contra la COVID-19; Janssen Pharmaceuticals, Inc. para desarrollar candidatos terapéuticos basados en ácidos nucleicos para el tratamiento del virus de la hepatitis B; Ultragenyx Pharmaceutical, Inc. para desarrollar candidatos terapéuticos de ARNm para dianas de enfermedades raras; CureVac AG para desarrollar candidatos terapéuticos y de vacunas de ARNm para diversas indicaciones; Singapore Economic Development Board y Duke-NUS Medical School para desarrollar la vacuna LUNAR-COV19; y Millennium Pharmaceuticals, Inc. para descubrir medicamentos de ARN de interferencia pequeño (siRNA) para el tratamiento de la esteatohepatitis no alcohólica. La compañía fue fundada en 2013 y tiene su sede en San Diego, California.

Nombre
Arcturus Therapeutics
CEO
Joseph E. Payne
Sede San Diego, ca
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
22/05/2013
Empleados 109

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
ARCT
🍪

Parqet  usa cookies. Más información